Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses

Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela's equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in horses. The license agreement is subject to, among other things, EQGen Biomedical securing financing from its extensive, qualified investor network.

"This is a very exciting opportunity for the development and commercialization of our stem cell product EQSTEM for the treatment of joint disease in horses. Xintela will actively participate in the development of EQSTEM, among other things, through process development and production of EQSTEM, on a fully funded, non-dilutive basis. Through this collaboration with EQGen Biomedical, we also get an excellent team associated with Regen Biomedical and Hummingbird Biomedical, with extensive experience in regenerative medicine, production, clinical development, business development as well as capital raising. We are very much looking forward to completing this license agreement and getting started on the collaboration with EQGen Biomedical", says Xintela's CEO Evy Lundgren-Åkerlund.

"I believe Xintela's unique equine stem cell product EQSTEM, purified using the stem cell marker integrin α10β1, has real potential to treat equine inflammatory and degenerative joint diseases, with current unmet medical need in approximately 30% of equines. EQGen Biomedical, is poised for success and with our deep expertise in clinical development as well as infrastructure for the development of regenerative therapies, we will be able to progress the clinical development of EQSTEM. I am very much looking forward to our collaboration", says EQGen Biomedical's Chief Medical Officer, Willem Scheele.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

This information is information that Xintela AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-23 23:15 CEST.

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser is Carnegie Investment Bank AB (publ).

Attachments

Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses